V8 Peptides — Engineered Performance
Research Library
Cagrilintide Receptor Pharmacology: In-Vitro Assays
CagrilintideMechanism

Cagrilintide Receptor Pharmacology: In-Vitro Assays

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

How is cagrilintide studied in in-vitro receptor binding and activation assays? Cagrilintide is a lipidated amylin analog, and amylin acts through the calcitonin receptor paired with RAMP1, 2 or 3 (AMY1R, AMY2R, AMY3R). Laboratories use competition binding and cAMP accumulation in defined cell lines, with a reference agonist, vehicle and parental-cell controls, and counter-screens against CGRP and adrenomedullin receptors. Albumin in the buffer shifts apparent potency of a lipidated analog, so report it. Laboratory research use only.

Cagrilintide is a lipidated analog of amylin, a 37-residue peptide hormone, and its pharmacology is unusual because amylin does not have a receptor of its own in the simple sense. Amylin signals through complexes: the calcitonin receptor, a class B G protein-coupled receptor, partnered with one of three accessory proteins. In-vitro binding and activation studies are how that complexity is resolved, and they are the main way a laboratory can use the cagrilintide research peptide as a tool compound. This article describes the receptor system, the assay formats used to probe it, what such assays can and cannot say about an acylated analog, and how to design and document one. It does not review structure or synthesis (see the cagrilintide research overview) and it makes no statement about effects in people. The material is for laboratory research use only.

The receptor system: one receptor, three partners

Amylin receptors (AMYRs) are heterodimers of the calcitonin receptor (CTR) and one of three receptor activity-modifying proteins, RAMP1, RAMP2 or RAMP3, forming AMY1R, AMY2R and AMY3R (Cao et al., 2022). The IUPHAR review of the calcitonin/CGRP family (Hay et al., 2018) places this in a wider family: calcitonin, α and β CGRP, amylin, adrenomedullin and adrenomedullin 2/intermedin act on receptors built from either CTR or the calcitonin receptor-like receptor, each combined with a RAMP. The review also stresses two complications that matter in a lab: CTR is probably co-expressed with CTR/RAMP complexes in many tissues, and species-dependent splice variants of CTR exist. In addition, the AMY1(a) receptor is activated about equally by amylin and CGRP, which means a CGRP response in a cell line does not rule out an amylin-receptor contribution.

Gingell and colleagues (2016) added a mechanistic layer: using molecular modeling with mutagenesis of the calcitonin receptor extracellular domain, assessed in binding and functional assays, they found that some residues matter for every peptide while others matter only when a RAMP is present, and concluded that RAMPs may allosterically influence the conformation of CTR. Practically, the same peptide can show different potency in cells that express CTR alone and in cells that express CTR with RAMP1, 2 or 3.

ReceptorComponentsNotes for assay design
CTRCalcitonin receptor aloneResponds to calcitonin; also to amylin, depending on the cell background and splice variant
AMY1RCTR + RAMP1Shares RAMP1 with the CGRP receptor system (as CLR/RAMP1); amylin and CGRP can both activate AMY1(a)
AMY2RCTR + RAMP2RAMP2 also partners CLR in the adrenomedullin AM1 receptor
AMY3RCTR + RAMP3RAMP3 also partners CLR in the AM2 receptor
CGRP receptorCLR + RAMP1Useful as a counter-screen to separate CGRP-family activity

What amylin pharmacology implies for an analog assay

Native amylin is hard to work with. Bower and Hay (2016) describe how its aggregative and solubility properties have limited structure-function studies, and note that the receptor composition complicates interpretation. The cagrilintide development paper (Kruse et al., 2021) describes the same problem from the design side: the hallmark of amylin is its propensity to form amyloid fibrils, and the lipidated analog was developed as a stable compound that avoids that behavior. For an in-vitro experiment the consequence is that an analog can be handled at stock concentrations that would be impractical for the native hormone, but that lipidation introduces its own considerations, which are albumin binding and surface adsorption.

Albumin binding is the one with a direct assay impact. The product page describes a fatty-acid side chain that promotes albumin binding. In an assay buffer containing serum or albumin, the free concentration of a lipidated analog is lower than the nominal concentration, and potency measured in the presence of albumin will be shifted to higher apparent concentrations than potency measured in a buffer without it. A laboratory should therefore report albumin content in the buffer, and, where possible, run parallel curves with and without it. This is a design point drawn from how acylated peptides bind albumin, not a number from the cited papers.

Assay formats for binding and activation

Receptor pharmacology separates two questions: does the compound bind, and does binding produce a response? The following formats are standard for class B GPCRs and are the ones used for amylin-family peptides in the cited literature; the table lists what each answers and a design caution.

FormatQuestion answeredDesign caution
Competition radioligand or fluorescent-ligand binding in membranes or cellsAffinity (Ki) relative to a labeled reference ligandReceptor expression level and RAMP stoichiometry change the apparent affinity
cAMP accumulation in cells expressing CTR with or without a RAMPGs-coupled functional potency (EC50) and efficacyInclude a reference agonist on every plate; check basal signal and phosphodiesterase inhibitor use
Other readouts (ERK phosphorylation, calcium, β-arrestin recruitment)Pathway bias and signaling beyond cAMPTime courses differ by pathway; use matched sampling times
Counter-screen against CGRP receptor and AM receptorsSelectivity within the familyNeeds cell lines with defined CLR/RAMP combinations
Antagonist shift (Schild-type) analysisWhether the response is receptor-mediated and by which receptorAntagonists available are of limited selectivity (Hay et al., 2018)

The structural work of Cao and colleagues (2022) gives a framework for interpreting such data. They determined structures of active AMYRs with amylin and with calcitonin peptides and found that amylin-bound AMYRs share a conformation constrained by the RAMP and an ordered midpeptide motif they call the bypass motif, while calcitonin-bound complexes were distinct. The authors conclude that activation of AMYRs by calcitonin-based peptides differs from activation by amylin-based peptides. For an assay this means that a peptide with calcitonin-like and amylin-like character cannot be assumed to behave as either: the receptor background in the cell line should be fully defined.

Controls, reference ligands and data analysis

A credible amylin-family binding or activation dataset includes a vehicle control matched to the diluent in every plate, a reference agonist (amylin or a characterized analog) to normalize efficacy, a null cell line lacking the receptor (or a parental line) to show the response is receptor dependent, and, where claims of receptor subtype are made, cell lines with defined CTR and RAMP expression verified by a method such as flow cytometry or a labeled-ligand binding assay. Concentration-response curves should span at least eight log-spaced points across four or more orders of magnitude, with replicates from independent preparations, fitted with a four-parameter logistic model, and reported with confidence intervals for the potency estimate.

Normalization conventions need stating: percentage of the reference agonist maximum or of forskolin response, whichever is used, and how the baseline was set. Differences between laboratories in potency values for the same peptide usually arise from differences in cell background, receptor expression, assay buffer and incubation time, not from the peptide, which is another reason to document the conditions fully.

Preparing the stock and keeping the concentration honest

The product page lists a 10 mg lyophilized vial, ≥98% purity by HPLC, formula C194H308N54O61 and storage at 2–8 °C with −20 °C for long-term holding, protected from heat, moisture and light. Concentration arithmetic follows c (mg/mL) = m (mg) ÷ V (mL) and, for molar work, c (µM) = [m (mg) ÷ MW (g/mol)] × 1000 ÷ V (mL), with MW taken from the lot documentation and the formula (approximately 4,400 g/mol, by the formula given on the product page). The reconstitution calculator handles the unit conversions, and how to reconstitute a lyophilized peptide describes the technique.

Three handling points matter more for a lipidated analog than for a short hydrophilic peptide. Add the diluent gently and swirl, because a molecule with a lipid chain is amphiphilic and foams easily. Use low-binding tubes and tips, because the lipid chain increases adhesion to plastic. And decide the assay vehicle before the stock: a stock made in water and diluted into buffer containing albumin behaves differently from one diluted into albumin-free buffer, as described above. Record the answers to each decision with the lot number. The product page states the COA as in progress; where a certificate is published for a lot it will be in the COA library, and how to read a COA explains what its fields establish.

Interpreting results and reporting them

An in-vitro dataset speaks to receptor-level behavior in a defined system, and nothing more. It cannot, without further work, predict behavior in tissues, because tissue receptor composition, co-expressed receptors, and albumin and protease environments differ. The reviews by Hay and colleagues (2015) and Bower and Hay (2016) both emphasize that the system is complicated by the multi-subunit nature of the receptor and by the limited selectivity of available tools, and that is a good guide to how cautiously to word conclusions. Report the cell background, receptor definition, buffer composition including albumin, ligand lot and purity method, stock verification, curve-fitting method and number of independent experiments, so that another laboratory can reproduce the work.

For comparisons with the unmodified-hormone drug class, see cagrilintide vs pramlintide; for combination designs with incretin-pathway peptides, the cagrisema combination research article; and for the analytical side, cagrilintide purity testing. All materials are for laboratory research use only.

Frequently asked questions

What receptors does amylin act on?

Amylin receptors are heterodimers of the calcitonin receptor with RAMP1, RAMP2 or RAMP3, called AMY1R, AMY2R and AMY3R. Amylin can also act at the calcitonin receptor alone, depending on the cell background.

Why do RAMPs matter in a binding assay?

RAMPs change ligand specificity and potency. Gingell and colleagues reported RAMP-dependent effects of receptor mutations and proposed that RAMPs allosterically influence calcitonin receptor conformation.

Is a CGRP response evidence against an amylin-receptor effect?

No. The AMY1(a) receptor is activated about equally by amylin and CGRP, so a CGRP counter-screen is useful but not decisive.

Which assays measure activation of amylin receptors?

cAMP accumulation in cells expressing the calcitonin receptor with or without a RAMP is the most common; ERK phosphorylation, calcium and β-arrestin recruitment probe other pathways.

Why does albumin matter for a lipidated analog?

The fatty-acid side chain promotes albumin binding, so free concentration and apparent potency depend on albumin in the buffer. Report albumin content and consider parallel curves with and without it.

What controls should an amylin-family assay have?

A diluent-matched vehicle, a reference agonist, a parental or null cell line, and cell lines with defined receptor composition when claiming subtype.

How do I calculate a molar stock concentration?

c (µM) = [m (mg) ÷ MW (g/mol)] × 1000 ÷ V (mL). Take MW from the lot documentation; the formula on the product page is C194H308N54O61.

Why handle the stock gently?

A lipidated analog is amphiphilic and tends to foam and stick to plastic. Swirl the vial, avoid shaking, and use low-binding consumables.

What did the 2022 structural study find?

Cao and colleagues reported that amylin-bound AMYR complexes share a conformation constrained by the RAMP and a bypass motif, while calcitonin-bound complexes are distinct, so activation by calcitonin-based peptides differs from activation by amylin-based peptides.

Do in-vitro results apply to people?

No. They describe receptor behavior in a defined cell system. The compound is sold for laboratory research use only and this article makes no claim about use in people.

Related reading: Cagrilintide Structure, Lipidation and Synthesis, Cagrilintide Primer: Names, Form and Lab Uses, Cagrilintide Rodent Studies: What Papers Report.

References

  1. Kruse T, Hansen JL, Dahl K, et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem. 2021;64(15):11183-11194. doi:10.1021/acs.jmedchem.1c00565
  2. Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD, Poyner DR. Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev. 2015;67(3):564-600. doi:10.1124/pr.115.010629
  3. Cao J, Belousoff MJ, Liang YL, et al. A structural basis for amylin receptor phenotype. Science. 2022;375(6587):eabm9609. doi:10.1126/science.abm9609
  4. Bower RL, Hay DL. Amylin structure-function relationships and receptor pharmacology: implications for amylin mimetic drug development. Br J Pharmacol. 2016;173(12):1883-1898. doi:10.1111/bph.13496
  5. Hay DL, Garelja ML, Poyner DR, Walker CS. Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25. Br J Pharmacol. 2018;175(1):3-17. doi:10.1111/bph.14075
  6. Gingell JJ, Simms J, Barwell J, et al. An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology. Cell Discov. 2016;2:16012. doi:10.1038/celldisc.2016.12

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.